Candel Therapeutics (CADL) Debt to Equity: 2020-2023
Historic Debt to Equity for Candel Therapeutics (CADL) over the last 2 years, with Sep 2023 value amounting to $0.89.
- Candel Therapeutics' Debt to Equity rose 129.99% to $0.89 in Q3 2023 from the same period last year, while for Sep 2023 it was $0.89, marking a year-over-year increase of 129.99%. This contributed to the annual value of $0.42 for FY2022, which is 4749.19% up from last year.
- According to the latest figures from Q3 2023, Candel Therapeutics' Debt to Equity is $0.89, which was up 34.21% from $0.66 recorded in Q2 2023.
- Candel Therapeutics' 5-year Debt to Equity high stood at $0.89 for Q3 2023, and its period low was -$0.02 during Q4 2020.
- Its 3-year average for Debt to Equity is $0.44, with a median of $0.40 in 2022.
- Data for Candel Therapeutics' Debt to Equity shows a peak YoY skyrocketed of 4,749.19% (in 2022) over the last 5 years.
- Over the past 4 years, Candel Therapeutics' Debt to Equity (Quarterly) stood at -$0.02 in 2020, then skyrocketed by 144.43% to $0.01 in 2021, then skyrocketed by 4,749.19% to $0.42 in 2022, then skyrocketed by 129.99% to $0.89 in 2023.
- Its Debt to Equity stands at $0.89 for Q3 2023, versus $0.66 for Q2 2023 and $0.51 for Q1 2023.